71 results about "Decoquinate" patented technology

The invention relates to a decoquinate solid dispersoid and a preparation method thereof. The decoquinate solid dispersoid consists of decoquinate and a macromolecular carrier which are added with proper amount of surfactant. The mass ratio of the decoquinate to the macromolecular carrier is 1:0.5-1:12, preferably 1:0.8-1:8, and optimally 1:1-1:5. The preparation method comprises the following steps: dissolving the macromolecular carrier into a corresponding solvent first, and then suspending the decoquinate in the obtained solution; adding the surfactant to the solution; homogenizing the mixture through a high-pressure homogenizer or a colloid mill; and smashing the mixture into fine powder after spray drying or reduced-pressure drying to obtain the decoquinate solid dispersoid. The decoquinate solid dispersoid solves the difficulty that the decoquinate has poor hydrophilia and is not easy to disperse in water, can be watered for use clinically and has more convenient application. The preparation method has the advantages of simple process, short production cycle, and low energy consumption without residual solvent, and is applicable to industrial production.

The invention belongs to the technical field of medicaments, and particularly relates to water soluble decoquinate and a method for preparing the same. The water soluble decoquinate comprises the following raw materials in percentage by weight: 6 to 20 percent of decoquinate, 60 to 89 percent of polymer carrier, and 5 to 20 percent of solubilizer. The method comprises the following steps: adding the decoquinate and the solubilizer to the fused polymer carrier for even mixing, or preparing the decoquinate, the solubilizer and the polymer carrier into corresponding organic solutions respectively, and evenly mixing the organic solutions; and drying the mixed solution to obtain the water soluble decoquinate. The method adopts the solid dispersion technology to prepare the decoquinate into the solid dispersion of the water soluble decoquinate, thereby improving the dissolution rate of the decoquinate, increasing the dissolubility of the decoquinate, improving the biological utilization rate of the decoquinate, facilitating the clinical application and adding the clinical application value of the decoquinate.

The invention provides ecoquinate soluble powder and a preparation method thereof. The preparation method comprises the steps: evenly mixing ecoquinate and a solid dispersion carrier together; heating the mixture to a fusing state at the temperature of 120DEG C to 150 DEG C; then, airing and crashing the mixture at room temperature; adding anhydrous dextrose to obtain the ecoquinate soluble powder. The decoquinate soluble powder comprises 1 percent to 20 percent of ecoquinate, 4 percent to 80 percent of solid dispersion carrier and anhydrous dextrose. The prepared soluble powder has good solubility and high stability, the property and the solubility of the soluble powder are not changed after being stored for 6 mouths under an accelerating test condition (40DEG C+ / -2DEG C) or being stored for 1 year at room temperature (25DEG C+ / -2DEG C ), the content of the ecoquinate soluble powder is reduced and meets the requirements of galenic pharmacy, the effective period of the ecoquinate soluble powder can be as long as 3 years by calculation, the content reduction is not obvious under an illumination experiment condition, and the content of drug active ingredients can be maintained above 90 percent for four hours in water. A prepared drug preparation has good effect and convenient use and has good popularization and application value.

The invention relates to a decoquinate nanoemulsion coccidium-resisting drug. The particle size of the decoquinate nanoemulsion coccidium-resisting drug is 1-100nm, the decoquinate nanoemulsion coccidium-resisting drug consists of, by mass percentage, decoquinate 0.1-6.0%, surface active agent 20.0-35.0%, cosurfactant 0-22.0%, cosolvent 1.0-3.0%, oil 1.5-12.0% and the balance distilled water. The drug is light yellow, is clear and transparent liquid visually, has the advantages of being good in stability, low in viscosity, strong in dispersibility, rapid in absorption and the like, and further has slow releasing and targeting effects. The bioavailability of the drug can be improved, half-life period of the drug in the body can be prolonged, and curative effect is enhanced. The decoquinate nanoemulsion coccidium-resisting drug is simple in preparation process, low in energy consumption, small in toxicity and high in safety, and can be produced in a mass mode without requiring special equipment.

The invention relates to a dry suspension formulation containing decoquinate and a preparation method thereof, which includes a solid dispersion carrier, a wetting agent, a diluent, a sweetener, and a suspending agent, and is prepared by a special process into a uniform The decoquinate dry suspension dispersed in water for chicken drinking water administration. The invention has the advantages of simple preparation process, stable quality, good suspension effect in water, good palatability and the like. Compared with the premix, it also has the advantages of fast onset of action, high bioavailability, and convenient use.

The invention relates to a preparation method of a decoquinate dry suspension. Decoquinate is uniformly dispersed in water through a special process to be administrated into chicken. The decoquinate dry suspension has the advantages of easily available adopted accessories, low cost, simple preparation process, stable quality, good suspension effect in water and the like. The decoquinate dry suspension, compared to a premix, is convenient to use, and is simple in preparation process in comparison with decoquinate soluble powder and suspension liquid.

The invention discloses a compound dimetridazole premix for preventing and treating the poultry enterovirus syndrome. The premix is prepared by uniformly mixing the following components in percentage by weight: 10 to 30 percent of dimetridazole, 4 to 10 percent of neomycin sulfate, 2 to 8 percent of decoquinate econazole nitrate, 10 to 30 percent of lysozyme, 0.5 to 5 percent of etamsylate, 3 to 10 percent of lactic acid TMP and the balance of pharmaceutically applicable auxiliary material. According to the invention, the novel high-efficiency anticoccidial drug decoquinate econazole nitrate, the dimetridazole and the neomycin sulfate which have a special curative effect on intestinal infection, the lysozyme with effects of resisting to bacteria, resisting to viruses, diminishing inflammation, relieving pain and repairing intestinal mucosa, the high-efficiency hemostatics etamsylate and the drug synergist are compounded into a compound preparation; and the compound dimetridazole premix has a high-efficiency treatment effect on the poultry enterovirus syndrome. The compound dimetridazole premix has a reasonable and scientific formula, is simple to prepare, has wide application and can be used as a priority drug for preventing and treating the poultry enterovirus syndrome.

The invention discloses a preparing method of deccox, which uses cheap pyrocatechol as material to obtain deccox products with good quality and low cost by diethoxylation, nitration, alkali hydrolysis, decyloxylation, reduction, condensation, ring closing and hydrolyzation. Compared with the prior art, materials such as 3,4-dihydroxynitrobenzene or catechol ethylether, which are expensive and not easy to buy, are replaced by chemical materials, such as plate caustic soda, pyrocatechol, diethyl sulfate, glacial acetic-acid, nitric acid, glycol monoethyl ether, potassium hydroxide, bromodecane, phosphorus oxychloride, ethoxymethylene, sodium hydroxide, etc., which are cheap and easy to obtain, the reaction condition is gental, the integration cost is 50% lower than that of the prior art.

The invention discloses a decoquinate nanometer preparation. The decoquinate nanometer preparation comprises decoquinate and an amphipathy surface active agent which is L-alpha phosphatidylcholine. The grain size of the decoquinate nanometer preparation is not larger than 300 nm. The dissolution rate of the active ingredient decoquinate is increased through introduction of the amphipathy surface active agent, the specific surface area of the decoquinate nanometer preparation with the grain size not larger than 300 nm is increased, the dissolution rate of the decoquinate is increased, and the absorption by the intestinal tract is effectively improved. In general, the dissolution rate of the decoquinate in the decoquinate nanometer preparation, the bioavailability and the malaria resisting drug effect are far higher than those of the micrometer decoquinate preparation. The invention further provides a preparing method for the decoquinate nanometer preparation. By means of introduction of the amphipathy surface active agent and an ultrasonic or high-pressure homogenate method, the micrometer decoquinate preparation is scattered into the decoquinate nanometer preparation.

The invention discloses a medicament for treating coccidiosis, particularly a novel compound anti-coccidiosis medicament and a preparation method thereof. The novel compound anti-coccidiosis medicament is characterized by being prepared from the following components: decoquinate, toltrazuril, polymer carrier, solubilizing agent and anhydrous dextrose. Therefore, the medicament has the advantages that: the indissoluble decoquinate and toltrazuril are prepared into water-soluble substances by using solid dispersion technology and inclusion technology, and the decoquinate and toltrazuril are mixed to fulfill the aim of reducing dosage, improving curative effect and reducing drug resistance; moreover, the synergistic effect of the medicaments can be realized by combining the decoquinate and the toltrazuril, the killing effect is enhanced and the dosage of each medicament is reduced by half.

The invention relates to the technical field of veterinary drug preparation and provides a preparation method of novel anticoccidial drug decoquinate. The preparation method includes steps that pyrocatechol monoethyl ether is used as a raw material, and the decoquinate is obtained through diazotization coupling reaction, decyl oxidation, reduction reaction, condensation reaction and cyclization reaction. The preparation method of the novel anticoccidial drug decoquinate is good in selectivity, high in operability, small in pollution, high in yield and suitable for large-scale production. Total yield of a target compound is about 45%.

The invention relates to an avian decoquinate oral suspension and a preparation method thereof, belonging to the technical field of veterinary drug preparations. The avian decoquinate oral suspension comprises the following components per 100ml: 5-15g of decoquinate, 0.5-10g of surfactant, 0.1-2g of binding agent, 0.1-2g of stabilizer and 100ml of volume-metered solvent. The avian decoquinate oral suspension overcomes the defects of nonuniform stirring of premixed preparation and insufficient absorption, and can be clinically used only by dilution so that the use method is simple and convenient; and in addition, the organic solvent of the avian decoquinate oral suspension is low in content, the cost of unit preparation is effectively reduced, and the problems of high preparation cost and difficult popularization and application of the traditional preparation are solved.

The invention relates to a coccidiostat-decoquinate dry suspension for livestock and poultry and a preparation method thereof. The coccidiostat comprises the following main components in portion by weight: 2 to 6 portions of decoquinate, 5 to 20 portions of non-ionic surfactant, and 30 to 90 portions of glauber salt. The preparation method comprises the following steps that: the decoquinate is added into the non-ionic surfactant, and the mixture is stirred evenly; and then the glauber salt is added into the mixture, and a finished product is prepared by stirring evenly, drying, crushing and sieving. The dry suspension is prepared from the decoquinate by adding the non-ionic surfactant and the glauber salt, solves the service restriction problem that the decoquinate fails to be taken by drinking water, greatly improves the clinical application range of decoquinate medicaments, and has broad application prospect.

The invention relates to a decoquinate solid dispersoid and a preparation method thereof. The decoquinate solid dispersoid consists of decoquinate and a macromolecular carrier which are added with proper amount of surfactant. The mass ratio of the decoquinate to the macromolecular carrier is 1:0.5-1:12, preferably 1:0.8-1:8, and optimally 1:1-1:5. The preparation method comprises the following steps: dissolving the macromolecular carrier into a corresponding solvent first, and then suspending the decoquinate in the obtained solution; adding the surfactant to the solution; homogenizing the mixture through a high-pressure homogenizer or a colloid mill; and smashing the mixture into fine powder after spray drying or reduced-pressure drying to obtain the decoquinate solid dispersoid. The decoquinate solid dispersoid solves the difficulty that the decoquinate has poor hydrophilia and is not easy to disperse in water, can be watered for use clinically and has more convenient application. Thepreparation method has the advantages of simple process, short production cycle, and low energy consumption without residual solvent, and is applicable to industrial production.

The invention relates to a coccidiostat-decoquinate dry suspension for livestock and poultry and a preparation method thereof. The coccidiostat comprises the following main components in portion by weight: 2 to 6 portions of decoquinate, 5 to 20 portions of non-ionic surfactant, and 30 to 90 portions of glauber salt. The preparation method comprises the following steps that: the decoquinate is added into the non-ionic surfactant, and the mixture is stirred evenly; and then the glauber salt is added into the mixture, and a finished product is prepared by stirring evenly, drying, crushing and sieving. The dry suspension is prepared from the decoquinate by adding the non-ionic surfactant and the glauber salt, solves the service restriction problem that the decoquinate fails to be taken by drinking water, greatly improves the clinical application range of decoquinate medicaments, and has broad application prospect.

The invention provides a decoquinate preparation as well as a preparation method and application thereof. According to the method provided by the invention, raw materials and auxiliary materials are low in price and a preparation process is simple; large-size high-end equipment is not needed and the decoquinate preparation can be relatively convenient and rapid to prepare; meanwhile, the prepared preparation has good dissolubility and dissolution. Meanwhile, in the preparation, decoquinate is matched with components including a wetting agent, a dispersant, a lipophilic surfactant, a soluble diluting agent and the like, so that tote dissolution of decoquinate can be effectively improved; furthermore, decoquinate can also be prepared into granules, tablets, dry suspension agents or premixing agents and meets the utilization requirements of different occasions; meanwhile, the decoquinate preparation can also be used for preparing medicines for treating coccus diseases and can achieve a good treatment effect.

The invention discloses a decoquinate oral micro-capsule preparation and a preparation process thereof, and in particular relates to a micro-capsule preparation, a preparation method of a novel coccidian chemical preparation for birds using decoquinate as a core material and sodium alga acid-chitosan as a composite capsule wall material, and a product, wherein the content of the alginate is 60-70 percent, the content of the chitosan is 10-20 percent, and the micro-capsule preparation is spherical or ellipsoidal and has a particle diameter of 40-80mu m. According to the invention, by coating decoquinate with sodium alga acid-chitosan, decoquinate hydrophilia is improved; and the prepared micro-capsule has a remarkable slow release function and is higher in chemical loading capacity.

The invention relates to a novel high-efficiency anticoccidial medicament, namely decoquinate solution and a preparation method thereof. The medicament mainly overcomes the disadvantages of complicated production process, inconvenience of dosing, inaccurate dosage, low parasite dispelling effect and the like of the conventional premix medicament. The medicament comprises the following components: a primary medicament, namely decoquinate, dimethylformamide, ethanol, propylene glycol, Tween 80, 85 to 90 percent of cosolvent, and 4 to 9 percent of triethanolamine. The preparation method for the medicament comprises the following steps of: introducing the dimethylformamide, the ethanol and the propylene glycol into a liquid distribution tank, adding the decoquinate and the cosolvent according to a formula, heating for dissolution, naturally cooling, and adding the Tween 80 and the propylene glycol according to the formula, and mixing uniformly. The invention has the advantages that: the production process is simple; and the product is stable in quality, simple in dosing operation, and accurate in dosage, and is dosed by a quantitative dosing device.

The invention discloses a decoquinate solution which comprises the following raw materials by weight: 5% of decoquinate, 75% of alcoholic solvents, 20% of dimethyl formamide. The invention also discloses a preparation method of the decoquinate solution. With the mode that decoquinate is dissolved in organic solvents, the decoquinate is in a solution form, and is administrated in an oral liquid form. Decoquinate is highly liposoluble, is difficult to dissolve in water and common organic solvents, has a low premix dissolution rate, and low bioavailability; when decoquinate is developed into a solvent through a pharmaceutical method, the administration is convenient, and the bioavailability is high.

The invention discloses a specific medicine used for treating coccidiosis and a preparation method of the specific medicine. The specific medicine is mainly prepared from diclazuril, decoquinate and toltrazuril. Every 100 ml of the medicament comprises, by weight, 0.45-0.55 g of diclazuril, 3.6-4.4 g of decoquinate and 1.8-2.2 g of toltrazuril. The preparation method comprises the fours steps of aqueous preparation, oil phase preparation, emulsion and dissolution promotion. The pecific medicine is mainly prepared from diclazuril, decoquinate and toltrazuril. The effect of treating the coccidiosis is improved through the synergistic effect of diclazuril, decoquinate and toltrazuril, and the drug resistance is lowered. Formed double solvents can effectively improve the solubility of the main medicine components in water, and main medicine can be stable in the preparation and is easily dissolved in water. Meanwhile, the special medicine has the advantages of being capable of taking effects fast, short in drug withdrawal period, high in death rate control and reduction, high in drug bioavailability and the like.

The invention relates to a compound anti-coccidiosis medicine, and belongs to the technical field of veterinary medicines. The compound anti-coccidiosis medicine is prepared from the following components in parts by weight: 0.01-0.1 part of methoxybenzyl aminopyrimidine, 0.02-0.3 part of sulfachloropyrazine sodium, 0.01-0.2 part of decoquinate, 20-30 parts of scutellaria baicalensis, 10-20 parts of puerarin, 5-15 parts of rheum officinale, 8-20 parts of white poria, 15-30 parts of caulis spatholobi and 7-25 parts of coriolus versicolor. The medicine provided by the invention has the beneficial effects that 1) the medicine combining traditional Chinese medicine and western medicine is good in curative effect and fast in effect, treats both symptoms and root causes and can effectively prevent and treat coccidiosis; 2) the compound anti-coccidiosis medicine has a remarkably synergic effect and the rate of preventing and treating coccidiosis is over 95%; and 3) the compound anti-coccidiosis medicine is conveneint to process and use.

The present invention relates to a hot melt extrusion composition, a process for preparing a hot melt extruded product using the hot melt extrusion composition, a solid dispersion of decoquinate, and pharmaceutical uses of the composition and the solid dispersion of decoquinate. The hot melt extrusion composition comprises 5 to 30% of decoquinate, 60 to 90% of a polymeric carrier and 0 to 10% of a surfactant. The hot melt extrusion composition can be melted into a liquid at a temperature below the melting point of decoquinate to achieve complete mixing, effectively avoiding the possible thermal decomposition of decoquinate and other components of the composition during the hot-melt process, thus retaining their original structures and pharmacodynamic activity. In the solid dispersion of decoquinate according to the present invention, the active pharmaceutical ingredient and the formulation excipients are melted into amorphous material with homogeneity, possessing improved solubility and drug releasing rate as well as enhanced oral bioavailability and efficacy.

The invention relates to a decoquinate liposome and a preparation method and application thereof. The preparation raw materials of the decoquinate liposome comprise the following components in parts by weight of 1 part of decoquinate and 2-20 parts of lecithin. The liposome is good in stability, shows favorable malaria resisting effects in and out of animal bodies, can be used for quickly relieving symptoms of malaria particularly subtertian malaria, and is high in safety. The preparation method is simple and feasible, and the decoquinate liposome has mass production potential.

The invention belongs to veterinary insect repellent medicine and preparing method technical field, and in particular relates to a decoquinate and lincomycin hydrochloride-containing pet insect repellent tablet and a preparation method thereof, the pet insect repellent tablet preparation comprises (a) decoquinate and lincomycin hydrochloride as raw material medicines, (b) an adhesive, (c) a wetting agent, (d) a disintegrating agent, (e) a filler and (f) a sweetener. The decoquinate and lincomycin hydrochloride-containing pet insect repellent tablet is prepared by a wet process, and is a white-like tablet in character. The decoquinate and lincomycin hydrochloride-containing pet insect repellent tablet is good in stability and good in palatability, and can be used a veterinary oral preparation.

The invention discloses a decoquinate dry suspension and a preparation method thereof, and belongs to the field of a veterinary preparation. The decoquinate dry suspension is prepared from a suspending aid, a solvent and an auxiliary material. The decoquinate dry suspension and the preparation method have the characteristics that the preparation method is simple; the settling volume ratio is high; the medicine content uniformity is good, and the like. The decoquinate dry suspension can be easily accepted by patients.

The invention provides a veterinary drug composition. The veterinary drug composition comprises, by mass, 5-25 parts of toltrazuril, 2.5-15 parts of decoquinate, 1-12 parts of pyrantel, 8-15 parts ofCortex Meliae, 2-8 parts of Chenopodium ambrosioides, 2-6 parts of Herb of Longseed Willowweed, 5-10 parts of Rhizoma Atractylodis Macrocephalae, 3-8 parts of dried orange peel and 5-10 parts of darkplum. The invention also provides a preparation method and an application of the veterinary drug composition. The veterinary drug composition has the advantages of reasonable compatibility, quick effect, minimal toxic and side effects, effective reduction of the drug resistance and drug residues, very clear therapeutic effect on intestinal injuries, reduced appetite and lean bodies of animals, caused by coccidiosis, low cost, and easiness in use. The invention further provides the application of the composition in the treatment of histomoniasis.

The present invention relates to a hot melt extrusion composition, a process for preparing a hot melt extruded product using the hot melt extrusion composition, a solid dispersion of decoquinate, and pharmaceutical uses of the composition and the solid dispersion of decoquinate. The hot melt extrusion composition comprises 5 to 30% of decoquinate, 60 to 90% of a polymeric carrier and 0 to 10% of a surfactant. The hot melt extrusion composition can be melted into a liquid at a temperature below the melting point of decoquinate to achieve complete mixing, effectively avoiding the possible thermal decomposition of decoquinate and other components of the composition during the hot-melt process, thus retaining their original structures and pharmacodynamic activity. In the solid dispersion of decoquinate according to the present invention, the active pharmaceutical ingredient and the formulation excipients are melted into amorphous material with homogeneity, possessing improved solubility and drug releasing rate as well as enhanced oral bioavailability and efficacy.

The invention relates to a Chinese and western medicine composition for preventing and treating rabbit Eimeria coccidiosis. The composition comprises the following traditional Chinese medicine ingredients in parts by weight: 20-50 parts of coptis root, 10-50 parts of radix scutellariae, 20-50 parts of radix dichroa, 20-40 parts of sweet wormwood, 10-30 parts of hairyvein agrimonia herb, 20-40 parts of garden burnet, 6-16 parts of decoquinate and 0.4-1.0 part of vitamin K3. The composition employs a Chinese and western medicine compound preparation; western medicine alleviates symptoms to reduce a death rate quickly; traditional Chinese medicine effects a permanent cure, improves the coccidium resistance of an organism essentially and eliminates coccidium influence; and the composition is convenient to use and lower in cost and has a good effect of preventing and treating the rabbit Eimeria coccidiosis.

The invention discloses a preparation method of decoquinate. Industrialized 2-hydroxyphenylacetic acid phenetole serves as starting materials, and a product with better quality is obtained through diazo coupling, sodium dithionite reduction, condensation, etherificationa and superstrong solid acid SO4<2-> / Fe2O3 and sodium bisulfate cyclization. Part intermediate of a synthetic route of the decoquinate does not need to be purified, used solvent is single, aftertreatment of the intermediate and use of organic solvent are reduced, the cost is reduced, the whole process route is short, extremely high temperature or highly corrosive liquid acid is not needed, requirement to equipment is low, operation is easy and convenient, the production cycle is short, produced three wastes are fewer, the production yield is high, the quality is good, and the preparation method of the decoquinate is suitable for industrial production.

The invention discloses a synthetic method of decoquinate, and belongs to the technical field of pharmaceutical engineering. The synthetic method takes o-hydroxyphenyl ethyl ether as a raw material to prepare decoquinate via the processes of coupling, reduction, condensation, etherification, cyclization and the like. The process of reduction in the method adopts environment-friendly hydrazine hydrate as a reducer to reduce an azo-compound and introduce an amino group, so that the synthetic method is good in selectivity, and environmentally friendly, and beneficial for reducing environmental pollution problems; BTC is adopted as a cyclization reagent in the process of cyclization, so that the condition is mild, the requirement on equipment is lowered, and the cost is reduced.